Polypeptide-polymer conjugates and methods of use thereof
The present invention provides polypeptide-polymer conjugates. A subject polypeptide-polymer conjugate is useful in a variety of applications, which are also provided.
1. A conjugate comprising:
a) a biologically active polypeptide having a molecular weight of from about 5 kDa to about 2000 kDa, and wherein the biologically active polypeptide is: i) a receptor; or ii) a ligand for a receptor; and
b) a biocompatible polymer having a molecular weight of at least about 50,000 Daltons,
wherein the polypeptide is covalently linked to the polymer directly or via a linker, and wherein the molar ratio of the biologically active polypeptide to the polymer is at least about 10:1.
2. The conjugate of claim 1 , wherein the polymer is a linear polymer comprising multiple subunits selected from hyaluronic acid, acrylic acid, ethylene glycol, methacrylic acid, acrylamide, hydroxyethyl methacrylate, mannitol, maltose, glucose, arabinose, taurine, betaine, modified celluloses, hydroxyethyl cellulose, ethyl cellulose, methyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, modified starches, hydrophobically modified starch, hydroxyethyl starch, hydroxypropyl starch, amylose, amylopectin, oxidized starch, and copolymers thereof.
3. The conjugate of claim 1 , wherein the biologically active polypeptide is a a ligand for a receptor.
4. The conjugate of claim 1 , wherein the polymer is linear poly(acrylic acid).
5. The conjugate of claim 1 , wherein the polymer is hyaluronic acid.
6. The conjugate of claim 1 , wherein the molar ratio of the biologically active polypeptide to the polymer is from about 10:1 to about 25:1.
7. The conjugate of claim 1 , wherein the molar ratio of the biologically active polypeptide to the polymer is from about 25:1 to about 50:1.
8. The conjugate of claim 1 , wherein the biologically active polypeptide has a molecular weight of from about 5 kDa to about 100 kDa.
9. A pharmaceutical composition comprising:
a) the conjugate of claim 1 ; and
b) a pharmaceutically acceptable excipient.
10. An implantable device comprising the conjugate of claim 1 .
11. The implantable device of claim 10 , wherein the implantable device is a stent, a shunt, an artificial valve, a lead, an artificial joint, a graft, or an electrode.
12. An implantable drug delivery device comprising the conjugate of claim 1 .
13. The conjugate of claim 1 , wherein the biologically active polypeptide is selected from a growth factor, an interleukin, a growth hormone, a colony stimulating factor, an interferon, or a neuroactive peptide.
14. The conjugate of claim 3 , wherein the biologically active polypeptide is selected from sonic hedgehog (Shh), bone morphogenic protein-4, interleukin-3 (IL-3), stem cell factor-1 (SCF-1), fms-like tyrosine kinase-3 ( Flt3) ligand, leukemia inhibitory factor (LIF), epidermal growth factor (EGF), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3), neurotrophin-4(NT-4), neurotrophin-5 (NT-5), basic fibroblast growth factor (bFGF), insulin-like growth factor-1 (IGF-1), glial-derived neurotrophic factor (GDNF), and protease nexin-1 .
15. The conjugate of claim 1 , wherein the biologically active polypeptide is a receptor.
16. The conjugate of claim 15 , wherein the biologically active polypeptide is a TNF-α-binding receptor, a vascular endothelial growth factor receptor, an interleukin receptor, a neurotransmitter receptor, or EphB2.
17. The conjugate of claim 1 , wherein the EC 50 of the polypeptide in the conjugate is at least 2-fold, at least 5-fold, or at least 10-fold lower than the EC 50 of the polypeptide in soluble form.
18. The conjugate of claim 5 , wherein the hyaluronic acid is sulfated.
19. The conjugate of claim 1 , wherein the biologically active polypeptide has a molecular weight of from about 10 kDa to about 2000 kDa.
20. The conjugate of claim 1 , wherein the biologically active polypeptide has a molecular weight of from about 50 kDa to about 2000 kDa.
21. The conjugate of claim 1 , wherein the EC 50 of the polypeptide in the conjugate is at least 25% lower than the EC 50 of the polypeptide in soluble form.
22. The conjugate of claim 1 , wherein the biological activity of the polypeptide of the conjugate is at least 25% greater than the biological activity of the polypeptide in soluble form.
23. The conjugate of claim 1 , wherein the conjugate comprises two or more species of biologically active polypeptide.